184 related articles for article (PubMed ID: 24101685)
1. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
[TBL] [Abstract][Full Text] [Related]
2. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
3. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
4. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.
Nguyen C; Faraggi M; Giraudet AL; de Labriolle-Vaylet C; Aparicio T; Rouzet F; Mignon M; Askienazy S; Sobhani I
J Nucl Med; 2004 Oct; 45(10):1660-8. PubMed ID: 15471830
[TBL] [Abstract][Full Text] [Related]
6. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.
Buscombe JR; Caplin ME; Hilson AJ
J Nucl Med; 2003 Jan; 44(1):1-6. PubMed ID: 12515868
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.
Buscombe JR; Cwikla JB; Caplin ME; Hilson AJ
Nucl Med Commun; 2005 Nov; 26(11):969-76. PubMed ID: 16208174
[TBL] [Abstract][Full Text] [Related]
9. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
[TBL] [Abstract][Full Text] [Related]
10. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
[TBL] [Abstract][Full Text] [Related]
11. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
[TBL] [Abstract][Full Text] [Related]
12. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
Lam MG; Lips CJ; Jager PL; Dullaart RP; Lentjes EG; van Rijk PP; de Klerk JM
J Clin Endocrinol Metab; 2005 Oct; 90(10):5888-95. PubMed ID: 16046591
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
14. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
15. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.
Taal BG; Hoefnagel CA; Valdes Olmos RA; Boot H; Beijnen JH
J Clin Oncol; 1996 Jun; 14(6):1829-38. PubMed ID: 8656251
[TBL] [Abstract][Full Text] [Related]
16. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors.
Sywak MS; Pasieka JL; McEwan A; Kline G; Rorstad O
World J Surg; 2004 Nov; 28(11):1157-62. PubMed ID: 15490060
[TBL] [Abstract][Full Text] [Related]
17. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
[TBL] [Abstract][Full Text] [Related]
18. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.
Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M
Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484
[TBL] [Abstract][Full Text] [Related]
19. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.
Grünwald F; Ezziddin S
Semin Nucl Med; 2010 Mar; 40(2):153-63. PubMed ID: 20113683
[TBL] [Abstract][Full Text] [Related]
20. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
